Urine PGE-M

A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia

J. Chad Johnson, Carl R. Schmidt, Martha J. Shrubsole, David D Billheimer, Prashant R. Joshi, Jason D. Morrow, Martin J. Heslin, M. Kay Washington, Reid M. Ness, Wei Zheng, David A. Schwartz, Robert J. Coffey, R. Daniel Beauchamp, Nipun B. Merchant

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background & Aims The enzyme cyclooxygenase-2 is expressed in a majority of colorectal carcinomas (CRCs) and is important in prostaglandin production. We have developed an accurate method to measure the urinary metabolite of prostaglandin E2 (PGE-M) using recently developed mass spectrometric techniques. The purpose of this pre-validation study was to determine if urinary PGE-M levels can be used as a biomarker to discriminate between healthy patients and those with colorectal disease. Methods Urine PGE-M was assessed in a total of 228 patients with CRC, colonic adenomatous polyps, Crohn's disease, and in subjects with no endoscopically detectable disease. Thirteen rectal carcinoma patients were treated with celecoxib and urinary PGE-M was measured before and after treatment. Results Urine PGE-M levels were increased among healthy men compared with healthy women (median, 8.59 [interquartile range (IQR), 5.67-22.3] vs 4.25 [IQR, 2.35-6.03], P = .0027). Urine PGE-M levels among patients with Crohn's disease (median, 19.85 [IQR, 6.89-90.2]), CRC (median, 14.65 [IQR, 5.94-92.1]), or large adenomas greater than 1 cm in size (median, 18.85 [IQR, 11.9-25.6]) were significantly increased when compared with patients who had either small polyps less than 1 cm in size (median, 9.69 [IQR, 6.41-22.2]), or no polyps (median, 7.05 [IQR, 2.35-24.7]) (P = .0001). PGE-M levels decreased significantly after celecoxib treatment in patients with rectal cancer (median, 21.7 [IQR, 16.2-29.9] vs 9.14 [IQR, 7.14-13.2], P = .009). Conclusions The increase in urinary PGE-M in patients with colorectal cancers and large adenomas suggests that urinary PGE-M is a potentially useful biomarker for the detection of advanced colorectal neoplasia.

Original languageEnglish (US)
Pages (from-to)1358-1365
Number of pages8
JournalClinical Gastroenterology and Hepatology
Volume4
Issue number11
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

Dinoprostone
Biomarkers
Urine
Celecoxib
Neoplasms
Colorectal Neoplasms
Polyps
Crohn Disease
Adenoma
Colonic Polyps
Adenomatous Polyps
7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid
Validation Studies
Cyclooxygenase 2
Rectal Neoplasms
Prostaglandins
Carcinoma
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Urine PGE-M : A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia. / Johnson, J. Chad; Schmidt, Carl R.; Shrubsole, Martha J.; Billheimer, David D; Joshi, Prashant R.; Morrow, Jason D.; Heslin, Martin J.; Washington, M. Kay; Ness, Reid M.; Zheng, Wei; Schwartz, David A.; Coffey, Robert J.; Beauchamp, R. Daniel; Merchant, Nipun B.

In: Clinical Gastroenterology and Hepatology, Vol. 4, No. 11, 11.2006, p. 1358-1365.

Research output: Contribution to journalArticle

Johnson, JC, Schmidt, CR, Shrubsole, MJ, Billheimer, DD, Joshi, PR, Morrow, JD, Heslin, MJ, Washington, MK, Ness, RM, Zheng, W, Schwartz, DA, Coffey, RJ, Beauchamp, RD & Merchant, NB 2006, 'Urine PGE-M: A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia', Clinical Gastroenterology and Hepatology, vol. 4, no. 11, pp. 1358-1365. https://doi.org/10.1016/j.cgh.2006.07.015
Johnson, J. Chad ; Schmidt, Carl R. ; Shrubsole, Martha J. ; Billheimer, David D ; Joshi, Prashant R. ; Morrow, Jason D. ; Heslin, Martin J. ; Washington, M. Kay ; Ness, Reid M. ; Zheng, Wei ; Schwartz, David A. ; Coffey, Robert J. ; Beauchamp, R. Daniel ; Merchant, Nipun B. / Urine PGE-M : A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia. In: Clinical Gastroenterology and Hepatology. 2006 ; Vol. 4, No. 11. pp. 1358-1365.
@article{55464b6fd2e8460baf33e11a629d0f33,
title = "Urine PGE-M: A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia",
abstract = "Background & Aims The enzyme cyclooxygenase-2 is expressed in a majority of colorectal carcinomas (CRCs) and is important in prostaglandin production. We have developed an accurate method to measure the urinary metabolite of prostaglandin E2 (PGE-M) using recently developed mass spectrometric techniques. The purpose of this pre-validation study was to determine if urinary PGE-M levels can be used as a biomarker to discriminate between healthy patients and those with colorectal disease. Methods Urine PGE-M was assessed in a total of 228 patients with CRC, colonic adenomatous polyps, Crohn's disease, and in subjects with no endoscopically detectable disease. Thirteen rectal carcinoma patients were treated with celecoxib and urinary PGE-M was measured before and after treatment. Results Urine PGE-M levels were increased among healthy men compared with healthy women (median, 8.59 [interquartile range (IQR), 5.67-22.3] vs 4.25 [IQR, 2.35-6.03], P = .0027). Urine PGE-M levels among patients with Crohn's disease (median, 19.85 [IQR, 6.89-90.2]), CRC (median, 14.65 [IQR, 5.94-92.1]), or large adenomas greater than 1 cm in size (median, 18.85 [IQR, 11.9-25.6]) were significantly increased when compared with patients who had either small polyps less than 1 cm in size (median, 9.69 [IQR, 6.41-22.2]), or no polyps (median, 7.05 [IQR, 2.35-24.7]) (P = .0001). PGE-M levels decreased significantly after celecoxib treatment in patients with rectal cancer (median, 21.7 [IQR, 16.2-29.9] vs 9.14 [IQR, 7.14-13.2], P = .009). Conclusions The increase in urinary PGE-M in patients with colorectal cancers and large adenomas suggests that urinary PGE-M is a potentially useful biomarker for the detection of advanced colorectal neoplasia.",
author = "Johnson, {J. Chad} and Schmidt, {Carl R.} and Shrubsole, {Martha J.} and Billheimer, {David D} and Joshi, {Prashant R.} and Morrow, {Jason D.} and Heslin, {Martin J.} and Washington, {M. Kay} and Ness, {Reid M.} and Wei Zheng and Schwartz, {David A.} and Coffey, {Robert J.} and Beauchamp, {R. Daniel} and Merchant, {Nipun B.}",
year = "2006",
month = "11",
doi = "10.1016/j.cgh.2006.07.015",
language = "English (US)",
volume = "4",
pages = "1358--1365",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Urine PGE-M

T2 - A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia

AU - Johnson, J. Chad

AU - Schmidt, Carl R.

AU - Shrubsole, Martha J.

AU - Billheimer, David D

AU - Joshi, Prashant R.

AU - Morrow, Jason D.

AU - Heslin, Martin J.

AU - Washington, M. Kay

AU - Ness, Reid M.

AU - Zheng, Wei

AU - Schwartz, David A.

AU - Coffey, Robert J.

AU - Beauchamp, R. Daniel

AU - Merchant, Nipun B.

PY - 2006/11

Y1 - 2006/11

N2 - Background & Aims The enzyme cyclooxygenase-2 is expressed in a majority of colorectal carcinomas (CRCs) and is important in prostaglandin production. We have developed an accurate method to measure the urinary metabolite of prostaglandin E2 (PGE-M) using recently developed mass spectrometric techniques. The purpose of this pre-validation study was to determine if urinary PGE-M levels can be used as a biomarker to discriminate between healthy patients and those with colorectal disease. Methods Urine PGE-M was assessed in a total of 228 patients with CRC, colonic adenomatous polyps, Crohn's disease, and in subjects with no endoscopically detectable disease. Thirteen rectal carcinoma patients were treated with celecoxib and urinary PGE-M was measured before and after treatment. Results Urine PGE-M levels were increased among healthy men compared with healthy women (median, 8.59 [interquartile range (IQR), 5.67-22.3] vs 4.25 [IQR, 2.35-6.03], P = .0027). Urine PGE-M levels among patients with Crohn's disease (median, 19.85 [IQR, 6.89-90.2]), CRC (median, 14.65 [IQR, 5.94-92.1]), or large adenomas greater than 1 cm in size (median, 18.85 [IQR, 11.9-25.6]) were significantly increased when compared with patients who had either small polyps less than 1 cm in size (median, 9.69 [IQR, 6.41-22.2]), or no polyps (median, 7.05 [IQR, 2.35-24.7]) (P = .0001). PGE-M levels decreased significantly after celecoxib treatment in patients with rectal cancer (median, 21.7 [IQR, 16.2-29.9] vs 9.14 [IQR, 7.14-13.2], P = .009). Conclusions The increase in urinary PGE-M in patients with colorectal cancers and large adenomas suggests that urinary PGE-M is a potentially useful biomarker for the detection of advanced colorectal neoplasia.

AB - Background & Aims The enzyme cyclooxygenase-2 is expressed in a majority of colorectal carcinomas (CRCs) and is important in prostaglandin production. We have developed an accurate method to measure the urinary metabolite of prostaglandin E2 (PGE-M) using recently developed mass spectrometric techniques. The purpose of this pre-validation study was to determine if urinary PGE-M levels can be used as a biomarker to discriminate between healthy patients and those with colorectal disease. Methods Urine PGE-M was assessed in a total of 228 patients with CRC, colonic adenomatous polyps, Crohn's disease, and in subjects with no endoscopically detectable disease. Thirteen rectal carcinoma patients were treated with celecoxib and urinary PGE-M was measured before and after treatment. Results Urine PGE-M levels were increased among healthy men compared with healthy women (median, 8.59 [interquartile range (IQR), 5.67-22.3] vs 4.25 [IQR, 2.35-6.03], P = .0027). Urine PGE-M levels among patients with Crohn's disease (median, 19.85 [IQR, 6.89-90.2]), CRC (median, 14.65 [IQR, 5.94-92.1]), or large adenomas greater than 1 cm in size (median, 18.85 [IQR, 11.9-25.6]) were significantly increased when compared with patients who had either small polyps less than 1 cm in size (median, 9.69 [IQR, 6.41-22.2]), or no polyps (median, 7.05 [IQR, 2.35-24.7]) (P = .0001). PGE-M levels decreased significantly after celecoxib treatment in patients with rectal cancer (median, 21.7 [IQR, 16.2-29.9] vs 9.14 [IQR, 7.14-13.2], P = .009). Conclusions The increase in urinary PGE-M in patients with colorectal cancers and large adenomas suggests that urinary PGE-M is a potentially useful biomarker for the detection of advanced colorectal neoplasia.

UR - http://www.scopus.com/inward/record.url?scp=33750828362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750828362&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2006.07.015

DO - 10.1016/j.cgh.2006.07.015

M3 - Article

VL - 4

SP - 1358

EP - 1365

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 11

ER -